(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/002986 A2

(51) International Patent Classification[7]: C07D 471/04, 487/04, 473/00, 405/08, A61K 31/41, 31/435, 31/52, A61P 25/00, 9/00, 3/00

(21) International Application Number: PCT/JP2003/008161

(22) International Filing Date: 26 June 2003 (26.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002-190978 28 June 2002 (28.06.2002) JP

(71) Applicant *(for all designated States except US)*: **BANYU PHARMACEUTICAL CO., LTD.** [JP/JP]; 2-3, Nihombashi Honcho 2-Chome, Chou-ku, Tokyo 103-8416 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OTAKE, Norikazu** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD. Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **MORIYA, Minoru** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD. Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **OGINO, Yoshio** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **MATSUDA, Kenji** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., 2-3, Nihonbashi Honcho 2-chome, Chuo-ku, TOKYO 103-8416 (JP). **NAGAE, Yoshikazu** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **KANATANI, Akio** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **FUKAMI, Takehiro** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP).


(74) Agent: **IWATANI, Ryo**; Sakurabashi Chiyoda Build., 5F, 1-27, Dojima 2-chome, Kita-ku, Osaka-shi, Osaka 530-0003 (JP).

(81) Designated States *(national)*: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, RU, SC, SG, SY, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NOVEL BENZIMIDAZOLE DERIVATIVES



(I)

(57) Abstract: A compound of the formula (I): (wherein A, B, C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is $^{-}N(SO_2R^4)$-, - N (COR^5) - or ^{-}CO-; Y is -C (R^6) (R^7)_, -0- or -N (R^8)_, provided that the compound (I) when E is nitrogen, n is 0, X is -CO-, and Y is $^{-}0$- is excluded) is useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome, hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation (Pickwickian syndrome), sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, and increased anesthetic risk.

WO 2004/002986 A2

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, RU, SC, SG, SY, TJ, TM, TN, TT, UA, UZ, VC, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.